Search

Your search keyword '"Secemsky, Eric"' showing total 1,272 results
Start Over Author "Secemsky, Eric"
1,272 results on '"Secemsky, Eric"'

2. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Author

Gornik, Heather L., Aronow, Herbert D., Goodney, Philip P., Arya, Shipra, Brewster, Luke Packard, Byrd, Lori, Chandra, Venita, Drachman, Douglas E., Eaves, Jennifer M., Ehrman, Jonathan K., Evans, John N., Getchius, Thomas S.D., Gutiérrez, J. Antonio, Hawkins, Beau M., Hess, Connie N., Ho, Karen J., Jones, W. Schuyler, Kim, Esther S.H., Kinlay, Scott, Kirksey, Lee, Kohlman-Trigoboff, Debra, Long, Chandler A., Pollak, Amy West, Sabri, Saher S., Sadwin, Lawrence B., Secemsky, Eric A., Serhal, Maya, Shishehbor, Mehdi H., Treat-Jacobson, Diane, and Wilkins, Luke R.

Published
2024
Full Text
View/download PDF

3. Temporal trends and outcomes of peripheral artery disease revascularization and amputation among the HIV population

Author

Teng, Alexandra E, Kennedy, Kevin F, Parikh, Rushi V, Armstrong, Ehrin J, Hsue, Priscilla Y, and Secemsky, Eric A

Subjects
Biomedical and Clinical Sciences, Public Health, Health Sciences, Infectious Diseases, Prevention, HIV/AIDS, Clinical Research, Cardiovascular, Amputation, Surgical, Endovascular Procedures, HIV Infections, Hospital Mortality, Humans, Limb Salvage, Peripheral Arterial Disease, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, amputation, HIV-associated cardiovascular disease, peripheral arterial disease, peripheral vascular intervention, Biological Sciences, Medical and Health Sciences, Psychology and Cognitive Sciences, Virology, Biomedical and clinical sciences, Health sciences
Abstract

ObjectiveWith antiretroviral therapy, people with HIV (PWH) are developing age-related diseases, including peripheral arterial disease (PAD). This study examined frequency and outcomes of peripheral vascular intervention (PVI) and primary amputation in PWH.DesignWe used the National Inpatient Sample (NIS) database to examine demographics, comorbidities, and temporal trends among PVI and primary amputation admissions by HIV status from 2012 to 2018.MethodsInverse probability of treatment weighting was used to calculate adjusted odds of in-hospital death and amputation. Cost of hospitalization and length of stay were compared by HIV status and revascularization approach.ResultsOf the 347 824 hospitalizations for PVI/amputation, 0.6% were PWH, which was stable over time. PWH had more renal and hepatic disease, whereas uninfected individuals had more traditional PAD risk factors. 55.2% of HIV+ admissions were endovascular compared with 49.3% in HIV- admissions, and 28.9% of the HIV+ admissions were elective compared with 42.1% among HIV-. HIV status did not impact amputation following PVI. In-hospital death was similar between groups following PVI or primary amputation. PWH had lower costs of hospitalization and a trend towards shorter hospital stays.ConclusionAlthough PWH are developing more age-related chronic illnesses, the number of PAD-associated procedures has remained flat. Despite being younger with fewer traditional PAD risk factors, PWH had higher rates of unplanned PVI admissions and endovascular revascularization but similar in-hospital outcomes. These findings suggest PWH have different risk factors for PAD and are likely underdiagnosed and undertreated, whereas those who are treated have similar outcomes to the general population.

Published
2022

7. A Safety and Feasibility Single-Arm Study of a Novel Catheter Thrombectomy Device for the Treatment of Pulmonary Embolism (ENGULF)

Author

Kobayashi, Taisei, Secemsky, Eric A., Klein, Andrew J., Faintuch, Salomao, Bulman, Julie C., Weinstein, Jeffrey L., Bitton-Faiwiszewski, Yonatan, Bisharat, Mohannad, Metzger, D. Christopher, Rosenberg, Russell D., Weinberg, Ido, Vadlamudi, Venu, Matthai, William H., Jr, Saleh, Amr, Cristea, Ecaterina, Lansky, Alexandra J., and Giri, Jay

Published
2024
Full Text
View/download PDF

9. Association of HIV infection with outcomes among adults hospitalized with COVID-19

Author

Durstenfeld, Matthew S, Sun, Kaiwen, Ma, Yifei, Rodriguez, Fatima, Secemsky, Eric A, Parikh, Rushi V, and Hsue, Priscilla Y

Subjects
Biomedical and Clinical Sciences, Public Health, Health Sciences, Clinical Research, Infectious Diseases, Cardiovascular, Prevention, HIV/AIDS, Good Health and Well Being, Adult, COVID-19, Female, HIV Infections, Hospital Mortality, Hospitalization, Humans, Male, SARS-CoV-2, United States, HIV, hospital, mortality, outcomes, Biological Sciences, Medical and Health Sciences, Psychology and Cognitive Sciences, Virology, Biomedical and clinical sciences, Health sciences
Abstract

ObjectiveThe aim of this study was to evaluate the association of HIV infection with outcomes among people hospitalized with COVID-19.DesignA prospectively planned analysis of the American Heart Association's COVID-19 Cardiovascular Disease Registry.SettingOne hundred and seven academic and community hospitals in the United States from March through December 2020.ParticipantsConsecutive sample of 21 528 adults hospitalized with COVID-19 at participating hospitals.Main outcome and measurePrimary outcome was predefined as in-hospital mortality. We used hierarchical mixed effects models to assess the association of HIV with in-hospital mortality accounting for patient demographics, comorbidities, and clustering by hospital. Secondary outcomes included major adverse cardiac events (MACE), severity of illness, and length of stay (LOS).ResultsThe registry included 220 people with HIV (PWH). PWH were younger and more likely to be male, Non-Hispanic Black, on Medicaid, and active tobacco users. Of the study population, 36 PWH (16.4%) died compared with 3290 (15.4%) without HIV [risk ratio 1.06; 95% confidence interval (95% CI) 0.79-1.43; P = 0.71]. After adjustment for age, sex, race, and insurance, HIV was not associated with in-hospital mortality (aOR 1.12; 95% CI 0.76-1.64; P = 0.58) with no change in effect after adding BMI and comorbidities (aOR 1.14; 95% CI 0.78-1.68; P = 0.51). HIV was not associated with MACE (aOR 0.99; 95% CI 0.69-1.44, P = 0.91), COVID severity (aOR 0.96; 95% CI 0.62-1.50; P = 0.86), or LOS (aOR 1.03; 95% CI 0.76-1.66; P = 0.21).ConclusionIn the largest study of PWH hospitalized with COVID-19 in the United States to date, we did not find significant associations between HIV and adverse outcomes including in-hospital mortality, MACE, or severity of illness.

Published
2022

10. Robustness of Longitudinal Safety and Efficacy After Paclitaxel-Based Endovascular Therapy for Treatment of Femoro-Popliteal Artery Occlusive Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Author

D'Oria, Mario, Mastrorilli, Davide, Secemsky, Eric, Behrendt, Christian-Alexander, Veraldi, Gianfranco, DeMartino, Randall, Mani, Kevin, Budtz-Lilly, Jacob, Scali, Salvatore, Saab, Fadi, Calvagna, Cristiano, Mezzetto, Luca, Ruaro, Barbara, and Lepidi, Sandro

Published
2024
Full Text
View/download PDF

13. Recent advances and controversial issues in the optimal management of asymptomatic carotid stenosis

Author

Paraskevas, Kosmas I., Brown, Martin M., Lal, Brajesh K., Myrcha, Piotr, Lyden, Sean P., Schneider, Peter A., Poredos, Pavel, Mikhailidis, Dimitri P., Secemsky, Eric A., Musialek, Piotr, Mansilha, Armando, Parikh, Sahil A., Silvestrini, Mauro, Lavie, Carl J., Dardik, Alan, Blecha, Matthew, Liapis, Christos D., Zeebregts, Clark J., Nederkoorn, Paul J., Poredos, Peter, Gurevich, Victor, Jawien, Arkadiusz, Lanza, Gaetano, Gray, William A., Gupta, Ajay, Svetlikov, Alexei V., Fernandes e Fernandes, Jose, Nicolaides, Andrew N., White, Christopher J., Meschia, James F., Cronenwett, Jack L., Schermerhorn, Marc L., and AbuRahma, Ali F.

Published
2024
Full Text
View/download PDF

15. An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Author

Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Ringleb, Peter Arthur, Brown, Martin M., Dardik, Alan, Poredos, Pavel, Gray, William A., Nicolaides, Andrew N., Lal, Brajesh K., Mansilha, Armando, Antignani, Pier Luigi, de Borst, Gert J., Cambria, Richard P., Loftus, Ian M., Lavie, Carl J., Blinc, Ales, Lyden, Sean P., Matsumura, Jon S., Jezovnik, Mateja K., Bacharach, J. Michael, Meschia, James F., Clair, Daniel G., Zeebregts, Clark J., Lanza, Gaetano, Capoccia, Laura, Spinelli, Francesco, Liapis, Christos D., Jawien, Arkadiusz, Parikh, Sahil A., Svetlikov, Alexei, Menyhei, Gabor, Davies, Alun H., Musialek, Piotr, Roubin, Gary, Stilo, Francesco, Sultan, Sherif, Proczka, Robert M., Faggioli, Gianluca, Geroulakos, George, Fernandes e Fernandes, Jose, Ricco, Jean-Baptiste, Saba, Luca, Secemsky, Eric A., Pini, Rodolfo, Myrcha, Piotr, Rundek, Tatjana, Martinelli, Ombretta, Kakkos, Stavros K., Sachar, Ravish, Goudot, Guillaume, Schlachetzki, Felix, Lavenson, George S., Jr., Ricci, Stefano, Topakian, Raffi, Millon, Antoine, Di Lazzaro, Vincenzo, Silvestrini, Mauro, Chaturvedi, Seemant, Eckstein, Hans-Henning, Gloviczki, Peter, and White, Christopher J.

Published
2024
Full Text
View/download PDF

19. Arterial Revascularization

Author

Ali, Ibrahim, Arslan, Bulent, Beasley, Robert, Bechara, Carlos, Berens, Pauline, Chandra, Venita, Chohan, Omar, Cote, Claudia, Dadrass, Farnaz, Dhand, Sabeen, Dua, Anahita, Elmasri, Fakhir, Fischer, Bryan, Hallak, Ahmad Omar, Han, Daniel K., Heaney, Carmen, Herman, Kevin, Jaffer, Uman, Jessula, Samuel, Kayssi, Ahmed, Keefe, Nicole, Khurana, Neal, Kohi, Maureen, Korff, Ricki A., Krishnan, Prakash, Kumar, Abhishek, Laurich, Chad, Lookstein, Robert A., Madassery, Sreekumar, Maringo, Alison, Martin, Jesse, Mathews, S. Jay, McCon, Reuben Perez, Mehta, Ankit, Melton, Jim G., Miranda, Jorge, Mize, Abigail, Baker, Miguel Montero, Mustapha, Jihad A., Nagi, Mohamed, N’Dandu, Zola, Osman, Murat, Parsons, Blake P., Posham, Raghuram, Raja, Aishwarya, Riaz, Rehan, Richard, Michele, Rundback, John H., Saab, Fadi A., Salazar, Gloria, Schiro, Brian J., Secemsky, Eric, Sommerset, Jill, Tabriz, David M., Taylor, Jordan, Thomas, Anish, Tummala, Srini, Tummala, Venkat, Uddin, Omar M., Van Den Berg, Jos, Watts, Micah, Wiechmann, Bret N., Ysa, August, Madassery, Sreekumar, editor, and Patel, Aesha, editor

Published
2023
Full Text
View/download PDF

20. Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice Findings From EXTEND-CoreValve

Author

Butala, Neel M, Secemsky, Eric, Kazi, Dhruv S, Song, Yang, Strom, Jordan B, Faridi, Kamil F, Brennan, J Matthew, Elmariah, Sammy, Shen, Changyu, and Yeh, Robert W

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Transplantation, Heart Disease, Clinical Research, Aging, Cardiovascular, Patient Safety, Clinical Trials and Supportive Activities, Aged, Aortic Valve, Aortic Valve Stenosis, Heart Valve Prosthesis Implantation, Humans, Medicare, Risk Factors, Transcatheter Aortic Valve Replacement, Treatment Outcome, United States, generalizability, real world, TAVR, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

ObjectivesThe aim of this study was to examine the applicability of pivotal transcatheter aortic valve replacement (TAVR) trials to the real-world population of Medicare patients undergoing TAVR.BackgroundIt is unclear whether randomized controlled trial results of novel cardiovascular devices apply to patients encountered in clinical practice.MethodsCharacteristics of patients enrolled in the U.S. CoreValve pivotal trials were compared with those of the population of Medicare beneficiaries who underwent TAVR in U.S. clinical practice between November 2, 2011, and December 31, 2017. Inverse probability weighting was used to reweight the trial cohort on the basis of Medicare patient characteristics, and a "real-world" treatment effect was estimated.ResultsA total of 2,026 patients underwent TAVR in the U.S. CoreValve pivotal trials, and 135,112 patients underwent TAVR in the Medicare cohort. Trial patients were mostly similar to real-world patients at baseline, though trial patients were more likely to have hypertension (50% vs 39%) and coagulopathy (25% vs 17%), whereas real-world patients were more likely to have congestive heart failure (75% vs 68%) and frailty. The estimated real-world treatment effect of TAVR was an 11.4% absolute reduction in death or stroke (95% CI: 7.50%-14.92%) and an 8.7% absolute reduction in death (95% CI: 5.20%-12.32%) at 1 year with TAVR compared with conventional therapy (surgical aortic valve replacement for intermediate- and high-risk patients and medical therapy for extreme-risk patients).ConclusionsThe trial and real-world populations were mostly similar, with some notable differences. Nevertheless, the extrapolated real-world treatment effect was at least as high as the observed trial treatment effect, suggesting that the absolute benefit of TAVR in clinical trials is similar to the benefit of TAVR in the U.S. real-world setting.

Published
2021

21. Comparative Outcomes of Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction Among Medicare Beneficiaries With Multivessel Coronary Artery Disease: An National Cardiovascular Data Registry Research to Practice Project

Author

Secemsky, Eric A, Butala, Neel, Raja, Aishwarya, Khera, Rohan, Wang, Yongfei, Curtis, Jeptha P, Maddox, Thomas M, Virani, Salim S, Armstrong, Ehrin J, Shunk, Kendrick A, Brindis, Ralph G, Bhatt, Deepak, and Yeh, Robert W

Subjects
Cardiovascular, Aged, Coronary Artery Disease, Humans, Medicare, Percutaneous Coronary Intervention, Registries, ST Elevation Myocardial Infarction, Time Factors, Treatment Outcome, United States, coronary artery disease, death, myocardial infarction, percutaneous coronary intervention, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Public Health and Health Services, Cardiovascular System & Hematology
Abstract

[Figure: see text].

Published
2021

26. Consensus minimum core data elements adapted to peripheral vascular intervention in the drug-eluting era: Consensus report from the Registry Assessment of Peripheral Interventional Devices (RAPID) Pathways “LEAN” working group

Author

Black, James H., 3rd, Buckley, Donna, Velezis, Martha, Eldrup-Jorgensen, Jens, Serratore, Nina D., Gutierrez, Jorge A., Whatley, Eleni, Marmor, Rebecca A., Bertges, Daniel J., Tcheng, James E., Royce, Sara, Malone, Misti, Farb, Andrew, Secemsky, Eric A., Parikh, Sahil A., Smale, Joshua, Jaff, Michael R., White, Roseann, Wilgus, Rebecca W., and Krucoff, Mitchell W.

Published
2023
Full Text
View/download PDF

32. Abstract 17709: ICD-10 Codes Have Low Sensitivity and Suboptimal Positive Predictive Value for Identifying Cases of Pulmonary Embolism With Cor Pulmonale in Electronic Healthcare Records

Author

Bejjani, Antoine, Khairani, Candrika D, Lo, Ying-Chih, Jimenez, David, Barco, Stefano, Mahajan, Shiwani, Caraballo, Cesar, Secemsky, Eric A, Klok, Erik, Hunsaker, Andetta, Aghayev, Ayaz, Muriel, Alfonso, Hussain, Mohamad A, Appah-Sampong, Abena, MOJIBIAN, HAMID, Lu, Yuan, Lin, Zhenqiu, Aneja, Sanjay, Khera, Rohan, Goldhaber, Samuel, Zhou, Li, Monreal, Manuel, Piazza, Gregory, Krumholz, Harlan M, and Bikdeli, Behnood

Published
2023
Full Text
View/download PDF

33. Abstract 17700: Double Trouble With Identification of Isolated Sub-Segmental Pulmonary Embolism Using ICD-10 Discharge Diagnosis Codes: The PE-EHR+ Study

Author

Bejjani, Antoine, Khairani, Candrika D, Lo, Ying-Chih, Jimenez, David, Barco, Stefano, Mahajan, Shiwani, Caraballo, Cesar, Secemsky, Eric A, Klok, Erik, Hunsaker, Andetta, Aghayev, Ayaz, Muriel, Alfonso, Hussain, Mohamad A, Appah-Sampong, Abena, MOJIBIAN, HAMID, Lu, Yuan, Lin, Zhenqiu, Aneja, Sanjay, Khera, Rohan, Goldhaber, Samuel, Zhou, Li, Monreal, Manuel, Krumholz, Harlan M, Piazza, Gregory, and Bikdeli, Behnood

Published
2023
Full Text
View/download PDF

34. Abstract 16342: Age- and Sex-Differences in Accuracy of ICD-10 Codes for Identifying Adults With Pulmonary Embolism: PE-EHR+ Study

Author

Mahajan, Shiwani, Lo, Ying-Chih, Bejjani, Antoine, Khairani, Candrika D, Jimenez, David, Barco, Stefano, Caraballo, Cesar, Secemsky, Eric A, Klok, Erik, Hunsaker, Andetta, Aghayev, Ayaz, Muriel, Alfonso, Hussain, Mohamad A, Appah-Sampong, Abena, MOJIBIAN, HAMID, Lu, Yuan, Lin, Zhenqiu, Aneja, Sanjay, Khera, Rohan, Goldhaber, Samuel, Zhou, Li, Monreal, Manuel, Piazza, Gregory, Krumholz, Harlan M, and Bikdeli, Behnood

Published
2023
Full Text
View/download PDF

35. Abstract 15011: Recent Trends in Interventional Treatment of Acute Pulmonary Embolism and Their Implications for a National Healthcare System

Author

Mohr, Katharina, Farmakis, Ioannis T, Barco, Stefano, Channick, Richard N, Christodoulou, Konstantinos, Giri, Jay S, Hobohm, Lukas, Keeling, Brent, Keller, Karsten, Lanno, Michelle, Lookstein, Robert A, Moriarty, John M, Reed, Jamie, Rosovsky, Rachel P, Rosenfield, Kenneth, Secemsky, Eric A, Todoran, Thomas M, Binder, Harald, and Konstantinides, Stavros V

Published
2023
Full Text
View/download PDF

39. Abstract 14344: Pitfalls of ICD-10 Codes for Identifying Pulmonary Embolism in Electronic Records: Results From the Multicenter PE-EHR+ Study

Author

Bikdeli, Behnood, Bejjani, Antoine, Khairani, Candrika D, Lo, Ying-Chih, Jimenez, David, Barco, Stefano, Mahajan, Shiwani, Caraballo, Cesar, Secemsky, Eric A, Klok, Erik, Hunsaker, Andetta, Aghayev, Ayaz, Muriel, Alfonso, Hussain, Mohamad A, Appah-Sampong, Abena, MOJIBIAN, HAMID, Lu, Yuan, Lin, Zhenqiu, Aneja, Sanjay, Khera, Rohan, Goldhaber, Samuel, Zhou, Li, Monreal, Manuel, Piazza, Gregory, and Krumholz, Harlan M

Published
2023
Full Text
View/download PDF

42. Update on paclitaxel for femoral-popliteal occlusive disease in the 15 months following a summary level meta-analysis demonstrated increased risk of late mortality and dose response to paclitaxel

Author

Schneider, Peter A, Varcoe, Ramon L, Secemsky, Eric, Schermerhorn, Marc, and Holden, Andrew

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Patient Safety, Cardiovascular, Clinical Research, Clinical Trials and Supportive Activities, Good Health and Well Being, Angioplasty, Balloon, Arterial Occlusive Diseases, Coated Materials, Biocompatible, Dose-Response Relationship, Drug, Femoral Artery, Follow-Up Studies, Global Health, Humans, Paclitaxel, Popliteal Artery, Survival Rate, Time Factors, Tubulin Modulators, Drug-coated balloon, Drug-eluting stent, Femoral-popliteal occlusive disease, Medical and Health Sciences, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences
Abstract

BackgroundPeripheral vascular devices (stents and balloons) coated with paclitaxel were developed to address suboptimal outcomes associated with percutaneous revascularization procedures of the femoral-popliteal arteries. In randomized controlled trials (RCT), paclitaxel-coated devices (PCD) provided increased long-term patency and a decreased need for repeat revascularization procedures compared with uncoated devices. This finding resulted in the adoption of their use for endovascular lower extremity revascularization procedures. However, in late 2018 a study-level meta-analysis showed increased all-cause mortality at 2 years or more after the procedure in patients treated with PCDs. This review examines the subsequent data evaluation following the publication of the meta-analysis.MethodsWe review the published responses of physicians, regulatory agencies, and patient advocates during 15-month period after the meta-analysis. We present the additional data gathered from RCTs that comprised the meta-analysis and safety outcomes from large insurance databases in both the United States and Europe.ResultsImmediately after the publication of the meta-analysis, concern for patient safety resulted in less PCD use, the suspension of large RCTs evaluating their use, and the publication of a letter from the U.S. Food and Drug Administration informing physicians that there was uncertainty in the benefit-risk profile of these devices for indicated patients and that the potential risk should be assessed before the use of PCDs. Review of the meta-analysis found that a mortality signal was present, but criticisms included that the evaluation was performed on study-level, not patient-level data, and the studies in the analysis were heterogenous in device type, paclitaxel doses, and patient characteristics. Further, the studies were not designed to be pooled nor were they powered for evaluating long-term safety. Clinical characteristics associated with a drug effect or causal relationship were also absent. Specifically, there was no dose response, no clustering of causes of death, and a lack of signal consistency across geographic regions. As more long-term data became available in the RCTs the strength of the mortality signal diminished and analysis of real-world use in large insurance databases, showed that there was no significant increase in all-cause mortality associated with PCD use.ConclusionsThe available data do not provide definitive proof for increased mortality with PCD use. A key observation is that trial design improvements will be necessary to better evaluate the risk-benefit profile of PCDs.

Published
2021

50. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease

Author

Gornik, Heather L., primary, Aronow, Herbert D., additional, Goodney, Philip P., additional, Arya, Shipra, additional, Brewster, Luke Packard, additional, Byrd, Lori, additional, Chandra, Venita, additional, Drachman, Douglas E., additional, Eaves, Jennifer M., additional, Ehrman, Jonathan K., additional, Evans, John N., additional, Getchius, Thomas S.D., additional, Gutiérrez, J. Antonio, additional, Hawkins, Beau M., additional, Hess, Connie N., additional, Ho, Karen J., additional, Jones, W. Schuyler, additional, Kim, Esther S.H., additional, Kinlay, Scott, additional, Kirksey, Lee, additional, Kohlman-Trigoboff, Debra, additional, Long, Chandler A., additional, Pollak, Amy West, additional, Sabri, Saher S., additional, Sadwin, Lawrence B., additional, Secemsky, Eric A., additional, Serhal, Maya, additional, Shishehbor, Mehdi H., additional, Treat-Jacobson, Diane, additional, and Wilkins, Luke R., additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results